EUVIMEDEUVIMED entdecken
FallberichtÜbersichtsarbeit

Extramammary Paget's disease treated with of anti‐programmed cell death protein 1 therapy after docetaxel therapy failure

Midori Narasaki, Junji Kato iD, Sayuri Sato iD, Tokimasa Hida iD, Kohei Horimoto iD, Yoshiyuki Matsui, Nobuaki Shigyo, Hisashi Uhara iD

The Journal of Dermatology · 2025

DOI: 10.1111/1346-8138.17500 ↗

Kurz gefasst

Fallbericht in der Zeitschrift The Journal of Dermatology, 2025. Verfasst von Midori Narasaki und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Sapporo Medical University School of Medicine, Sapporo, Japan. Hauptthemen laut MEDLINE: Paget Disease, Extramammary, Docetaxel, Programmed Cell Death 1 Receptor, Skin Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 8 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Extramammary Paget's disease (EMPD) is a rare skin cancer with no standard treatment for advanced‐stage disease. Although docetaxel‐based chemotherapy is common, no standard treatment exists. Pembrolizumab is approved for solid tumors with a high tumor mutation burden (TMB) and/or high microsatellite instability, and nivolumab was approved in Japan in February 2024 for unresectable advanced or recurrent epithelial skin malignancies. However, there is a lack of real‐world data regarding the efficacy of anti‐programmed cell death protein 1 (PD‐1) therapy for EMPD. We present the case details of three EMPD patients treated with anti‐PD‐1 therapy after docetaxel treatment, with TMB values of 17.8, 14.3, and 5.0 mut/Mb, respectively, and we review similar reported cases. Even in the cases with a high TMB, the response to anti‐PD‐1 therapy was not sufficient. Most cases involve second‐line or later treatments, so further research is needed to determine the precise effectiveness of anti‐PD‐1 therapy as a first‐line treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Paget Disease, ExtramammaryDocetaxelProgrammed Cell Death 1 ReceptorSkin NeoplasmsImmune Checkpoint InhibitorsHumansAgedFemaleMaleTreatment FailureAged, 80 and overNivolumabAntibodies, Monoclonal, HumanizedMiddle AgedSkin

Stichwörter der Autor:innen

EMPDICIPD‐1TMBextramammary Paget disease

Substanzen

DocetaxelProgrammed Cell Death 1 ReceptorPDCD1 protein, humanImmune Checkpoint InhibitorsNivolumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Dermatology, Sapporo Medical University School of Medicine, Sapporo, Japan.

ORCID-Profile: Junji Kato, Sayuri Sato, Tokimasa Hida, Kohei Horimoto, Hisashi Uhara

Zitieren

APA

Narasaki, M., Kato, J., Sato, S., Hida, T., Horimoto, K., Matsui, Y., Shigyo, N., & Uhara, H. (2025). Extramammary Paget's disease treated with of anti‐programmed cell death protein 1 therapy after docetaxel therapy failure. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.17500

Vancouver

Narasaki M, Kato J, Sato S, Hida T, Horimoto K, Matsui Y, et al. Extramammary Paget's disease treated with of anti‐programmed cell death protein 1 therapy after docetaxel therapy failure. The Journal of Dermatology. 2025. doi:10.1111/1346-8138.17500

BibTeX
@article{Narasaki2025,
  author = {Narasaki, Midori and Kato, Junji and Sato, Sayuri and Hida, Tokimasa and Horimoto, Kohei and Matsui, Yoshiyuki and Shigyo, Nobuaki and Uhara, Hisashi},
  title = {Extramammary Paget's disease treated with of anti‐programmed cell death protein 1 therapy after docetaxel therapy failure},
  journal = {The Journal of Dermatology},
  year = {2025},
  doi = {10.1111/1346-8138.17500}
}
Kostenlos starten →